Business Context and Reporting Period
This Form 8-K Current Report was filed by Eli Lilly and Company on August 13, 2024. The report addresses corporate governance changes rather than financial performance for a specific fiscal period.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the departure of a director from the Board of Directors.
Management Commentary and Risks
Dr. Marschall S. Runge notified the Board of his decision to retire, effective August 31, 2024. The Company explicitly stated that this retirement did not arise from any disagreement with the Company regarding operations, policies, or practices. A press release detailing this announcement was issued on August 16, 2024.
Key Facts for Investors to Verify
- Dr. Marschall S. Runge will retire from the Board of Directors on August 31, 2024.
- The departure is voluntary and unrelated to any disputes with the Company.
- Investors should review the attached press release (Exhibit 99.1) for further details on the transition.
- Financial performance data is not included in this filing; refer to the most recent 10-Q or 10-K for financial metrics.